AuthorisedTherapeutic use (Phase IV)Interventional

GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE ADMITTED IN THE EMERGENCY ROOM - A FEASIBILITY STUDY

This study, called GLIFLOFASTER, is focused on older patients who have chronic heart failure and have recently been admitted to the emergency room because their heart failure worsened. Researchers want to see if starting a medication called dapagliflozin early can help these patients. The main aim is to understand how practical it is to set up and run this study in hospitals, check how many patients agree to take part, and see how well they follow the treatment plan. They will also look at how many patients stay on the medicine, complete their follow-up, and whether the study runs on time. Ultimately, this research hopes to learn if this early treatment could be a good option for improving care for people with heart failure.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

Centre Hospitalier Regional Universitaire

Enrolment target

144

Start

31 Mar 2026

CHRONIC DECOMPENSATED HEART FAILURE

What is this study about?

Imagine your heart suddenly struggles more than usual, leading you to the hospital. This often happens to people who have 'chronic heart failure,' which means their heart has been weakened over time. This study is aimed at older patients who experience this sudden worsening, often called 'decompensated heart failure,' and end up in the emergency room.

The main goal of the GLIFLOFASTER study is to figure out if it's practical to give a specific heart medication called dapagliflozin to these patients early on. Researchers want to understand if hospitals can easily set up the necessary procedures, how many patients are willing to join, and whether patients find it easy to take the medication and attend follow-up appointments. This type of study helps make sure any future research is well-planned and patient-friendly.

Beyond just looking at how practical it is, the study will also look at important health outcomes after three months. They'll check things like whether patients need to go back to the hospital, if their quality of life improves or gets worse, and how their heart failure symptoms and certain blood markers change. This information helps doctors understand if this early treatment could make a real difference in how older patients with heart failure recover and manage their condition.

Key takeaways

Targets older patients with worsened chronic heart failure after an emergency hospital visit.
Investigates starting dapagliflozin treatment early.
Primarily checks how practical it is to run the study and for patients to participate.
Looks at patient rehospitalisation, quality of life, and symptoms over 3 months.
Aims to improve care for people with heart failure.

Who may be eligible?

This study is looking for participants of any age who have recently been admitted to the emergency room because their chronic heart failure has suddenly worsened. Both men and women are welcome to take part in this research.

There aren't any specific age restrictions mentioned, meaning adult patients of various ages might be considered if they meet the criteria of having chronic heart failure and a recent hospital visit for it. The most important factor for joining is having this specific heart condition and experiencing a recent flare-up that required emergency care.

Quick self-check

Have I been diagnosed with chronic heart failure?
Have I recently been admitted to the emergency room because my heart failure worsened?
Am I open to taking a new heart medication?
Am I able to attend follow-up appointments or phone calls over 3 months?

This is a guide only — the research team will confirm whether you can take part.

What does participation involve?

If you take part in this study, you would be taking a medication called dapagliflozin. Researchers will keep a close eye on your health. This involves checking your symptoms and kidney function at specific times, especially when you leave the hospital and again after 7 days, and then at 3 months. You might have phone calls to check in on you and ensure you're doing well and taking your medication as prescribed. The study will track your progress for about 3 months, looking at things like hospital visits and how you feel.

Potential risks and benefits

Taking part in this study might offer a potential benefit if dapagliflozin helps stabilize your heart failure and improves your well-being. However, as with any medication, there can be risks or side effects, which your doctor will discuss with you. You are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

—
France

Common questions

What is chronic heart failure?

Chronic heart failure means your heart isn't pumping blood as well as it should, leading to symptoms like breathlessness, tiredness, and swelling.

What is dapagliflozin?

Dapagliflozin is a medication, often used for conditions like diabetes, but it has also shown benefits in helping people with heart failure.

What does 'early treatment' mean in this study?

It means giving the dapagliflozin medication soon after you've been in hospital because your heart failure suddenly got worse.

Why is this study called a 'feasibility study'?

A feasibility study checks if a new plan or treatment can be successfully carried out. Here, it's about seeing if giving this medicine early is practical and manageable.

Will I get better if I join this study?

Researchers are hoping to learn if this treatment helps, but there's no guarantee you will get better. The study aims to gather information to help future patients.